Compare JPMorgan Equity Premium Income ETF (JEPI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.78 (market cap $45.69B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 6.1× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| JEPI | SYRE | |
|---|---|---|
Market Cap | $45.69B | $7.52B |
Volume | 3,633,306 | 1,441,031 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $108.92 |
52-Week Low | $55.29 | $22.18 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93 with minimal daily movement (-0.05%) and maintains a bullish technical outlook based on moving averages. The ETF continues its consistent dividend distribution strategy with recent payments of $0.37 per share. Technical indicators show mixed signals with RSI levels ranging from neutral to overbought, while the overall trend remains positive.
The covered-call strategy provides income stability but may limit upside during strong market rallies. Recent media coverage highlights JEPI's role in retirement income strategies, though investors should consider tax implications and income limitations compared to pure equity exposure.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
